Shambhunath Choudhary1, Hwa-Chain Robert Wang. 1. Department of Pathobiology, College of Veterinary Medicine, The University of Tennessee, 2407 River Drive, Knoxville, TN 37996, USA.
Abstract
PURPOSE: To verify the pro-apoptotic activity of oncogenic H-Ras in the increased susceptibility of human cancer cells to histone deacetylase inhibitor (HDACI). METHODS: The pro-apoptotic activity of oncogenic H-Ras(V12) was verified by its ability to increase susceptibility of human colorectal adenocarcinoma HT29 cells to HDACI for inducing apoptosis and growth inhibition, assayed by various methods. The mode of action of HDACI FR901228 was studied by its ability to modulate protein phosphorylation, acetylation, and expression levels in various signaling pathways, measured by Western blot analysis. RESULTS: Activation of caspase-3, -7, and -8, and serine protease by FR901228 was facilitated by oncogenic H-Ras to induce apoptosis. Expression of H-Ras(V12) changed the intrinsic modulation of Raf in cells responding to FR901228 treatment. Both p21( Cip1 ) and p27( Kip1 ) were induced in FR901228-treated cells arrested in either the G0/G1 or G2/M phase of the cell cycle. Deacetylation of FR901228-induced acetylation of core histones was accelerated by H-Ras(V12) in cells undergoing apoptosis. CONCLUSION: Expression of H-Ras(V12) increased susceptibility of HT29 cells to HDACI FR901228 and Trichostatin A for inducing apoptosis. The pro-apoptotic activity of H-Ras(V12) responding to HDACI indicates a potential value of this new class of anticancer agents in treating Ras-related human cancers.
PURPOSE: To verify the pro-apoptotic activity of oncogenic H-Ras in the increased susceptibility of humancancer cells to histone deacetylase inhibitor (HDACI). METHODS: The pro-apoptotic activity of oncogenic H-Ras(V12) was verified by its ability to increase susceptibility of humancolorectal adenocarcinoma HT29 cells to HDACI for inducing apoptosis and growth inhibition, assayed by various methods. The mode of action of HDACI FR901228 was studied by its ability to modulate protein phosphorylation, acetylation, and expression levels in various signaling pathways, measured by Western blot analysis. RESULTS: Activation of caspase-3, -7, and -8, and serine protease by FR901228 was facilitated by oncogenic H-Ras to induce apoptosis. Expression of H-Ras(V12) changed the intrinsic modulation of Raf in cells responding to FR901228 treatment. Both p21( Cip1 ) and p27( Kip1 ) were induced in FR901228-treated cells arrested in either the G0/G1 or G2/M phase of the cell cycle. Deacetylation of FR901228-induced acetylation of core histones was accelerated by H-Ras(V12) in cells undergoing apoptosis. CONCLUSION: Expression of H-Ras(V12) increased susceptibility of HT29 cells to HDACI FR901228 and Trichostatin A for inducing apoptosis. The pro-apoptotic activity of H-Ras(V12) responding to HDACI indicates a potential value of this new class of anticancer agents in treating Ras-related humancancers.
Authors: R V Talanian; C Quinlan; S Trautz; M C Hackett; J A Mankovich; D Banach; T Ghayur; K D Brady; W W Wong Journal: J Biol Chem Date: 1997-04-11 Impact factor: 5.157
Authors: Sara Sánchez-Molina; José Luis Oliva; Susana García-Vargas; Ester Valls; José M Rojas; Marian A Martínez-Balbás Journal: Biochem J Date: 2006-09-01 Impact factor: 3.857
Authors: E C de Bruin; D Meersma; J de Wilde; I den Otter; E M Schipper; J P Medema; L T C Peltenburg Journal: Cell Death Differ Date: 2003-10 Impact factor: 15.828
Authors: Romel Somwar; Sandra Koterski; Gary Sweeney; Richard Sciotti; Stevan Djuric; Cathy Berg; James Trevillyan; Philipp E Scherer; Christina M Rondinone; Amira Klip Journal: J Biol Chem Date: 2002-10-21 Impact factor: 5.157
Authors: Pawat Pattarawat; Jessica T Hunt; Jacob Poloway; Collin J Archibald; Hwa-Chain Robert Wang Journal: Cancer Chemother Pharmacol Date: 2021-05-27 Impact factor: 3.288